Welcitam 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and preventing seizure propagation. Welcitam 500 is typically prescribed as adjunctive therapy in patients who do not achieve adequate seizure control with monotherapy or as monotherapy in newly diagnosed epilepsy. The drug is well-absorbed orally, with rapid onset of action and minimal hepatic metabolism, reducing the risk of drug interactions. Dosage should be individualized based on clinical response and tolerability, with gradual titration recommended to minimize adverse effects such as dizziness, somnolence, irritability, and fatigue. Caution is advised in patients with renal impairment, necessitating dose adjustment. Welcitam 500 should be used under strict medical supervision, with regular monitoring for efficacy and side effects. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients. Patient adherence and regular follow-up are essential to optimize therapeutic outcomes and minimize seizure recurrence.